

Naura Technology (002371 CH)

Building for the next leg of WFE growth

Naura reported FY25 revenue of RMB39.4bn, up 31% YoY and broadly in line with our and Bloomberg consensus, while net profit declined 1.8% YoY to RMB5.5bn, below expectations due to heavier R&D investment and opex associated with increased hiring and Kingsemi consolidation. While 4Q margin came under pressure, we view this primarily as a result of intensified product validation rather than deterioration in end demand. Encouragingly, the Company continued to deliver strong top-line momentum on robust IC equipment growth (50%+ YoY) and ongoing product expansion into higher-value process steps. We remain positive on Naura's positioning as a core beneficiary of China's WFE localization trend and domestic foundry capex expansion. Maintain BUY and raise TP to RMB540, based on 35x 2027E P/E (prev. 35x 2026E P/E), as we look through near-term margin headwinds and focus on the sequential recovery and the anticipated earnings inflection in 2027E.

■ **Naura's etching and deposition segment revenue both exceeded RMB10bn in FY25**, driving IC equipment revenue growth of more than 50% YoY, per mgmt. We believe this performance shows Naura's strengthening position in China's domestic WFE supply chain. Looking ahead, new product offerings such as 12-inch PVD, vertical furnace systems and HBM-related hybrid bonding solutions should support deeper penetration into logic, memory and advanced packaging, providing a broader and higher-quality growth runway into 2026E and beyond. We expect IC equipment sales to grow by over 40% YoY in 2026E.

■ **Near-term profitability softened on investment and validation but should improve as scale benefits emerge.** Naura's 4Q margins were pressured by elevated component upgrade costs during client validation for new products and weaker profitability in non-IC segments such as PV. At the same time, Naura continued to invest aggressively for future growth, with R&D expenses up 46% YoY and admin expenses rising 102% YoY following the Kingsemi consolidation and headcount expansion. We expect profitability to improve progressively as validated tools move into volume production, product mix shifts further toward IC equipment, and operating leverage strengthens into 2H26.

■ **Maintain BUY with TP revised to RMB540, based on its three-year historical forward average P/E.** We remain bullish on China's WFE sector, as accelerating domestic substitution and sustained capex from logic and memory foundries continue to reinforce a strong multi-year growth backdrop. With the most comprehensive WFE portfolio among domestic peers, Naura is positioned to capture this opportunity across a broadening range of process steps. We expect margin expansion to reaccelerate from 2027E onward, driven by a more favorable mix shift toward higher-margin advanced-node products and stronger operating leverage as scale continues to build.

Earnings Summary

(YE 31 Dec)	FY24A	FY25A	FY26E	FY27E	FY28E
Revenue (RMB mn)	30,075	39,353	51,977	65,752	81,559
YoY growth (%)	36.2	30.9	32.1	26.5	24.0
Gross margin (%)	42.9	40.1	40.1	41.5	43.0
Net profit (RMB mn)	5,621.8	5,522.0	7,739.4	11,048.9	15,594.7
YoY growth (%)	44.2	(1.8)	40.2	42.8	41.1
EPS (Reported) (RMB)	7.83	7.64	10.71	15.30	21.59
P/E (x)	60.2	61.6	44.0	30.8	21.8
ROE (%)	20.3	16.1	18.7	22.1	25.0

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price	RMB540.00
(Previous TP	RMB460.00)
Up/Downside	14.6%
Current Price	RMB471.23

China Semiconductors

Kevin ZHANG

(852) 3761 8727

kevinzhang@cmbi.com.hk

Aaron GUO

(852) 3916 3715

aaronguo@cmbi.com.hk

Stock Data

Mkt Cap (RMB mn)	340,387.8
Avg 3 mths t/o (RMB mn)	3,682.8
52w High/Low (RMB)	523.88/299.42
Total Issued Shares (mn)	722.3

Source: FactSet

Shareholding Structure

Beijing Sevenstar Huadian Technology Gro	33.6%
Beijing Electronics Holding	9.4%


Source: Bloomberg

Share Performance

	Absolute	Relative
1-mth	0.5%	-5.8%
3-mth	-8.4%	-11.2%
6-mth	17.8%	3.2%

Source: FactSet

12-mth Price Performance



Source: FactSet

Figure 1: Earnings revision

RMBmn	New			Old			Diff (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	51,977	65,752	81,559	49,588	59,236	N/A	4.8%	11.0%	N/A
Gross profit	20,851	27,316	35,082	21,174	25,649	N/A	-1.5%	6.5%	N/A
Net profit	7,739	11,049	15,595	9,399	11,502	N/A	-17.7%	-3.9%	N/A
EPS (RMB)	10.71	15.30	21.59	13.03	15.95	N/A	-17.8%	-4.1%	N/A
Gross margin	40.1%	41.5%	43.0%	42.7%	43.3%	N/A	-2.6 ppt	-1.8 ppt	N/A
Net margin	14.9%	16.8%	19.1%	19.0%	19.4%	N/A	-4.1 ppt	-2.6 ppt	N/A


Source: Company data, CMBIGM estimates

Figure 2: CMBIGM estimates vs. BBG consensus

RMBmn	CMBIGM			BBG Consensus			Diff (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	51,977	65,752	81,559	51,002	65,354	82,362	1.9%	0.6%	-1.0%
Gross profit	20,851	27,316	35,082	20,560	26,047	32,777	1.4%	4.9%	7.0%
Net profit	7,739	11,049	15,595	8,225	11,062	15,554	-5.9%	-0.1%	0.3%
EPS (RMB)	10.71	15.30	21.59	11.35	15.27	19.59	-5.6%	0.2%	10.2%
Gross margin	40.1%	41.5%	43.0%	40.3%	39.9%	39.8%	-0.2 ppt	1.7 ppt	3.2 ppt
Net margin	14.9%	16.8%	19.1%	16.1%	16.9%	18.9%	-1.2 ppt	-0.1 ppt	0.2 ppt


Source: Bloomberg consensus, CMBIGM estimates

Figure 3: Forward P/E chart



Source: Bloomberg data, CMBIGM estimates

Figure 4: P/E band



Source: Bloomberg data, CMBIGM estimates

Figure 5: Peers table

		Mkt Cap	P/E (x)			GPM%		
Company	Ticker	(US\$m)	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Domestic peers								
AMEC	688012 CH	28,873	62.0	44.3	32.8	41.0	41.5	40.7
PIOTECH	688072 CH	16,185	67.3	46.7	31.5	41.2	43.2	41.7
ACMR	688082 CH	11,085	37.4	29.9	20.9	48.5	48.9	48.2
		Average	55.6	40.3	28.4	43.6	44.6	43.5
Overseas peers								
ASML	ASML NA	569,721	40.2	30.8	26.7	52.6	54.0	55.1
TEL	8035 JT	131,337	30.4	26.1	22.9	45.2	47.2	48.1
Lam Research	LRCX US	334,171	42.9	32.6	28.9	49.6	49.7	50.2
		Average	46.7	35.1	27.3	46.4	47.4	47.3

Source: Bloomberg consensus as of 17 Apr 2026, CMBIGM

Financial Summary

INCOME STATEMENT	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (RMB mn)						
Revenue	22,079	30,075	39,353	51,977	65,752	81,559
Cost of goods sold	(13,005)	(17,162)	(23,571)	(31,127)	(38,435)	(46,477)
Gross profit	9,075	12,913	15,782	20,851	27,316	35,082
Operating expenses	(4,627)	(6,366)	(9,980)	(12,322)	(14,911)	(17,729)
Selling expense	(167)	(179)	(237)	(287)	(330)	(369)
SG&A expense	(2,836)	(3,265)	(5,069)	(5,925)	(6,970)	(7,993)
R&D expense	(2,475)	(3,699)	(5,435)	(7,173)	(9,074)	(11,255)
Others	852	777	762	1,063	1,462	1,887
Operating profit	4,448	6,546	5,802	8,528	12,405	17,353
Other income	22	22	51	0	0	0
Other expense	(4)	(35)	(8)	0	0	0
Pre-tax profit	4,466	6,533	5,845	8,528	12,405	17,353
Income tax	(433)	(819)	(436)	(636)	(926)	(1,295)
After tax profit	4,033	5,714	5,409	7,892	11,480	16,058
Minority interest	134	92	(113)	152	431	463
Net profit	3,899	5,622	5,522	7,739	11,049	15,595

BALANCE SHEET	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (RMB mn)						
Current assets	38,226	46,669	59,321	67,285	81,490	105,909
Cash & equivalents	12,451	12,396	17,337	15,718	21,620	35,134
Account receivables	3,767	6,236	8,217	10,296	13,123	15,926
Inventories	16,992	23,635	28,627	36,185	39,633	46,954
Prepayment	1,480	909	863	980	1,168	1,466
Other current assets	3,535	3,494	4,277	4,106	5,946	6,429
Non-current assets	15,399	19,696	30,480	34,667	40,030	46,648
PP&E	3,352	6,314	7,568	7,795	8,132	8,551
Right-of-use assets	215	241	268	224	209	203
Deferred income tax	450	712	1,239	1,406	1,676	2,104
Intangibles	2,547	4,710	10,520	13,008	15,944	19,395
Goodwill	27	38	2,386	2,386	2,386	2,386
Other non-current assets	8,808	7,681	8,498	9,848	11,683	14,008
Total assets	53,625	66,366	89,801	101,952	121,521	152,556
Current liabilities	19,083	23,805	26,180	38,792	45,978	58,330
Short-term borrowings	23	94	319	7,920	9,711	13,759
Account payables	6,117	10,276	11,803	16,339	18,411	23,609
Tax payable	209	384	586	665	792	995
Other current liabilities	3,418	5,577	7,491	7,078	8,970	9,806
Contract liabilities	8,317	6,220	4,291	4,872	5,807	7,290
Accrued expenses	999	1,253	1,690	1,919	2,287	2,871
Non-current liabilities	9,717	10,021	19,693	11,910	13,636	17,415
Long-term borrowings	5,835	3,946	12,973	4,390	4,827	6,562
Bond payables	0	0	0	0	0	0
Deferred income	4	1	487	487	487	487
Other non-current liabilities	3,877	6,074	6,233	7,034	8,323	10,367
Total liabilities	28,800	33,826	45,873	50,702	59,614	75,745
Share capital	530	534	725	725	725	725
Retained earnings	8,776	13,895	18,802	25,940	36,167	50,608
Other reserves	15,061	16,653	18,200	18,231	18,231	18,231
Total shareholders equity	24,367	31,082	37,726	44,896	55,122	69,563
Minority interest	458	1,458	6,202	6,354	6,785	7,248
Total equity and liabilities	53,625	66,366	89,801	101,952	121,521	152,556

CASH FLOW	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (RMB mn)						
Operating						
Profit before taxation	4,466	6,533	5,845	8,528	12,405	17,353
Depreciation & amortization	730	1,071	1,567	2,453	3,071	3,829
Tax paid	(433)	(819)	(436)	(636)	(926)	(1,295)
Change in working capital	(3,409)	(6,364)	(6,766)	(5,508)	(4,311)	(4,704)
Others	1,012	1,152	1,923	(1,386)	(1,411)	(1,036)
Net cash from operations	2,365	1,572	2,133	3,450	8,829	14,147
Investing						
Capital expenditure	(1,980)	(2,046)	(3,436)	(4,382)	(5,346)	(6,386)
Acquisition of subsidiaries/ investments	(81)	(173)	0	0	0	0
Net proceeds from disposal of short-term investments	3	0	0	0	0	0
Others	0	8	(3,645)	1,244	1,408	1,624
Net cash from investing	(2,058)	(2,212)	(7,081)	(3,138)	(3,937)	(4,762)
Financing						
Dividend paid	(388)	(615)	(822)	(936)	(1,175)	(1,613)
Net borrowings	1,888	132	8,677	(982)	2,227	5,783
Proceeds from share issues	212	1,280	1,730	0	0	0
Others	(66)	(68)	(41)	(17)	(48)	(48)
Net cash from financing	1,647	729	9,544	(1,936)	1,004	4,122
Net change in cash						
Cash at the beginning of the year	10,261	12,229	12,385	17,183	15,565	21,466
Exchange difference	14	5	(14)	5	6	7
Others	1,954	33	4,812	(1,623)	5,896	13,506
Cash at the end of the year	12,229	12,267	17,183	15,565	21,466	34,980
GROWTH	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Revenue	50.3%	36.2%	30.9%	32.1%	26.5%	24.0%
Gross profit	40.9%	42.3%	22.2%	32.1%	31.0%	28.4%
Operating profit	55.1%	47.2%	(11.4%)	47.0%	45.5%	39.9%
Net profit	65.7%	44.2%	(1.8%)	40.2%	42.8%	41.1%
PROFITABILITY	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Gross profit margin	41.1%	42.9%	40.1%	40.1%	41.5%	43.0%
Operating margin	20.1%	21.8%	14.7%	16.4%	18.9%	21.3%
Return on equity (ROE)	17.7%	20.3%	16.1%	18.7%	22.1%	25.0%
GEARING/LIQUIDITY/ACTIVITIES	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Current ratio (x)	2.0	2.0	2.3	1.7	1.8	1.8
VALUATION	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
P/E	86.4	60.2	61.6	44.0	30.8	21.8

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY	: Stock with potential return of over 15% over next 12 months
HOLD	: Stock with potential return of +15% to -10% over next 12 months
SELL	: Stock with potential loss of over 10% over next 12 months
NOT RATED	: Stock is not rated by CMBIGM

OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.